A Sit Down With Cancer

Slideshow

A doctor sits down with Cancer to gauge its feelings towards new immunotherapy agents, lower smoking rates, and the US obesity epidemic.

As we bid farewell to last year, let us note that several exciting advances in the treatment of cancer were approved in 2017. New immunotherapy agents with high response rates against recalcitrant tumors led some of us optimistic types to believe that for the first time we might have unearthed the secret to victory. I tried to remain cool and collected while daydreaming about the day when this vile disease is eradicated, but my enthusiasm got the best of me and, like a cheeky reporter, I went so far as to schedule an interview with Cancer, in order to gauge how sanguine it feels about the future. Like Porfiry Petrovitch, the magistrate in Crime and Punishment who questions the murderer Raskolnikov, I sat down with Cancer, ready to interrogate it under the klieg lights. Here are some excerpts from our conversation.Caption/concept by Craig R. Hildreth, MDArtwork by Jon Carter, cartertoons.com

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients.
3 experts are featured in this series.
Related Content